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This study analyzes the survival of patients with type II diabetes mellitus and factors that affect it using 
survival analysis.  The survival analysis was conducted by Kaplan Meier curves and Cox regression 
equations of interaction models. In this study, 1293 patients with type II diabetes mellitus, with 10.36% 
(n = 134 patients) death. Patients aged ≥45 years 88.86% (n = 1149), 53.29% women (n = 689), 71.15% 
(n = 920) with comorbidities, 56.84% (n = 735) high blood glucose levels, and 49.03% (n = 634) 
received a combination of insulin-oral antidiabetic therapy. Factors related to the patient's survival are 
the interaction of gender variables with age variables (p <0.05; HR = 0.841; CI 95% 0.711-0.993), 
variable interaction of blood glucose levels while with variable age (p  <0,05; HR = 1,061; CI 95% 
1,028-1,096), variable interaction of blood glucose levels with comorbidity variables (p <0,05; HR 
1,221; CI 95% 1,036-1,438), and variable interaction of blood glucose levels with variable treatment 
profiles (p  <0,05; HR = 0.824; CI 95% 0.747-0.909). Factors that affect the survival of patients with 
type II diabetes mellitus are age, gender, diagnosis complications, comorbidity, intermittent blood 
glucose levels, and treatment profiles.  
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INTRODUCTION 
Type II diabetes mellitus is a group of 
metabolic diseases with characteristic 
hyperglycemia1 that occur due to abnormalities 
of insulin secretion, insulin work, or both.2 
This disease is one of the world's health threats, 
including in Indonesia. Based on primary 
health research data in 2018, the prevalence of 
diabetes mellitus in the ≥15-year-old 
population in Indonesia increased from 1.5% 
in 2013 to 2.0% in 2018.3 WHO3 estimates that 
people with diabetes mellitus will continue to 
increase up to 2-3 times by 2035.4 Patients 
aged 20-79 are expected to increase to 642 
million, with most low- and middle-income 
countries.5 
The mortality rate due to diabetes mellitus 
ranges from 0.28-8.24 per 100 patients-years 
with the highest mortality in older patients and 
longer.6 According to the IDF, 5.0 million 
people died in 2015, while 415 million were 
injured.5 Diabetic Mellitus patients who have 
complications with hypertension and poor 
blood glucose control have a higher risk of 
failure.7 Not only that, renal complications7-10, 
cardiovascular7,11, and peripheral 
circulation14,15 also increase the risk of 
mortality of type II diabetes mellitus patients. 
Survival analysis is a statistical technique 
that has been widely used in health sciences16-
18 to analyze the chances of death, recurrence, 
survival, and other events at any given time.19 
Accurate predictions regarding the externality 
or survival rate of diabetic patients can be 
critical to levels of prognosis and therapy. 
Therefore, this study was conducted to assess 
the length of life, therapy, and factors that 
affect survival. It is expected to have a linear 
impact on the length of life of diabetes mellitus 
patients. 
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MATERIAL AND METHODS 
This research was descriptive research, 
where the data used was the medical record 
data of patients with type II diabetes mellitus 
who undergo hospitalization and outpatient at 
two hospitals, namely PKU Muhammadiyah 
Gamping Hospital and PKU Muhammadiyah 
Hospital Yogyakarta, Indonesia. Inclusion 
criteria: Patients diagnosed with Type II 
Diabetes Mellitus are ≥18 years old and 
undergo treatment from 2015 to 2019. Patients 
diagnosed with diabetes mellitus type I and 
gestational diabetes illegible medical records 
and incomplete data was excluded. 
Data retrieval was conducted 
retrospectively by collecting all data related to 
this study, from the initial events of patients 
diagnosed with type II diabetes mellitus to the 
observation period. It aimed to determine the 
survival of patients with type II diabetes 
mellitus and the factors that affect it. The 
patient's survival was known based on the 
patient's survival status (life/death) and 
survival time measured when the patient was 
diagnosed with type II diabetes mellitus until 
the time the data was taken. The required data 
were patient name, gender, age, history of 
disease, complications, when first diagnosed 
with Diabetes Mellitus type II, therapy 
regimen used, and laboratory results in the 
form of blood glucose levels. This research has 
obtained ethical clearance from the Research 
Ethics Commission of PKU Muhammadiyah 
Hospital Yogyakarta No. 
0011/KT.7.4/VIII/2020. 
In this study, there were several research 
variables, namely patient survival status, survival 
time, gender (X1), age (X2), concomitant 
disease (X3), complications (X4), treatment 
profile (X5), and current blood glucose levels 
(X6). The data that has been obtained is 
classified and coded according to existing 
variables. Variables of patient survival status, 
gender, and accompanying disease are grouped 
into dichotomous data. Survival time was 
expressed in units of years. The age variable 
was grouped into two levels, namely <45 years 
and ≥45 years. Variable complications were 
divided into: without complications, renal 
complications, peripheral circulation 
complications, multi complication, coma, 
cardiovascular complications, and other 
complications. The variable profile of 
treatment was divided into insulin, oral 
antidiabetics, and a combination of oral 
insulin-antidiabetics. Variable blood glucose 
levels was divided into: Normal (<140 mg/dL), 
Moderate (140-199 mg/dL), and High (≥ 200 
mg/dL). 
In this study, the Kaplan Meier method was 
used to know the characteristics of survival 
time.   In addition, the Log Rank test was used 
to determine the difference in survival curve 
between groups of factors that affect the survival 
of patients with type II diabetes mellitus with p < 
0.05. Proportional hazard assumption testing 
was conducted with two tests, namely visual 
test using Kaplan Meier method and formal test 
using Goodness of fit test. The total covariate 
result of cox regression p<0.05 was included in 
the equation model.  The data was analyzed 
using SPSS 25 software. 
The models or formulas for predicting 
hazard functions and survival functions are as 
follows. 
a. Hazard Function 
H(t)= H0(t)ey           (1)   
H(t)= H0(t)e0.337 (X6-X2) -0.199 (X6-X3)-0.059 (X4-X6)- 
0,174 (X1-X2)-0.193 (X6-X5) 
 
b. Survival Function 





In this study, there were 1293 data of type 
II diabetes mellitus patients as seen in Table 1, 
10.36% (n = 134) were non-survivor patients 
or died, and 89.64% (n = 1159) were survivor 
patients or still surviving during the period 
2015-2019. In non-survivor patients, there 
were 70 male patients and 64 female patients; 
126 patients were ≥45 years old, 76 patients 
were diagnosed with complications, 109 
patients with comorbidity, and moderately 
elevated blood glucose levels were identified.  
Based on research that has been done, 
obtained data on the overall number of patients 
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with type II diabetes mellitus aged ≥45 years 
more (88.86%) than patients who are <45 years 
old. In the sex variables, 53.29% of type II 
diabetes mellitus patients were female, while 
46.71% were male. The most common 
complications are peripheral circulation 
complications.  The majority of patients 
(71.15%) had comorbidity, and 56.84 percent 
of type II diabetes mellitus patients had 
hyperglycemia, while 49.03 percent received 
insulin-oral antidiabetic combination therapy, 
44.01 percent received oral antidiabetic 




Table 1. Frequency Distribution of Characteristics of Type II Diabetes Mellitus Patients at PKU 
Muhammadiyah Gamping Hospital and Yogyakarta City  
Variable n (%) 
Survival Status   
• Life 1159 89,64 
• Died 134 10,36 
Gender   
• Male 604 46,71 
• Women 689 53,29 
Age   
• <45 years old 144 11,14 
• ≥45 years old 1149 88,86 
Diagnosis of Complications   
• Without Complications 719 55,61 
• Renal Complications 56 4,33 
• Neurology Complications 171 13,23 
• Peripheral Circulation Complications 199 15,39 
• Multicomplication 37 15,39 
• Coma 34 2,63 
• Cardiovascular Complications 76 5,33 
• Other Complications 1 0,08 
Comorbidity   
• Without Comorbidity 373 28,85 
• With Comorbidity 920 71,15 
Treatment Profile   
• Insulin 90 6,96 
• Oral antidiabetics 569 44,01 
• Combination 634 49,03 
Blood Glucose Levels   
• Normal 102 7,89 
• Moderate 456 35,27 
• High 735 56,84 
Table 2.  The Goodness of Fit Test Results of Type II Diabetes Mellitus Patients at PKU 
Muhammadiyah Gamping Hospital and Yogyakarta City 
 T G Age DC C BGL (mg/dL) 
Chi-Square 409,592 5,588 781,148 2402,23 231,407 467,012 
Df 2 1 1 7 1 2 
Asymp. Sig 0,000 0,018 0,000 0,000 0,000 0,000 
  
Note : T = Therapy, G = Gender, DC = Diagnose of Complications, C = Comorbidity, BGL = Blood 
Glucose Level, df = degree of freedom 
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(a)                                                                      (b)     
 
 
(c)                                                                     (d) 
 
 
                                    (e)                                                                      (f) 
 
Figure 1. Kaplan Meier curves each factor. (a) Gender; (b) Age; (c) Complications; (d) 
Comorbidity; (e) Treatment Profile; (f) Blood Glucose Levels. 
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Table 3. Cox Regression Results of Type II Diabetes Mellitus Patient Interaction Model at PKU 
Muhammadiyah Gamping Hospital and Yogyakarta City 
 
 B SE df Sig. Exp(B) 
95,0% CI for Exp(B) 
Lower Upper 
Sex*Age -0,174 0,085 1 0,041 0,841 0,711 0,993 
Blood Glucose Levels *Age 0,337 0,092 1 0,000 1,401 1,169 1,678 
Complications*Treatment Profile 0,059 0,016 1 0,000 1,061 1,028 1,096 
Blood Glucose Levels*  Comorbidity 0,199 0,083 1 0,017 1,221 1,036 1,438 
Blood Glucose Levels* Treatment Profile -0,193 0,050 1 0,000 0,824 0,747 0,909 
 
Description: B = Slope Value or Beta Coefficient of Constants; SE = Standard Error; df = degree of 
freedom; Sig. = Significance or p-value Wald test; Exp(B) = Exponential Beta Coefficient 
 
Hazard proportional assumption testing 
was also conducted with the Goodness of Fit 
test approach. This test was conducted to 
obtain more objective decisions. In this test, H0 
means factors that were suspected to affect the 
survival of patients with diabetes mellitus type 
II meet the assumption of proportional hazard, 
while H1 means that factors that were 
suspected to affect the survival of patients with 
type II diabetes mellitus do not meet the 
assumption of proportional hazard. Reject 
decision H0 if p-value < α = 5%. Here were the 
results of the hazard proportional assumption 
test using the Goodness of Fit test. Based on 
table 2, it is concluded that all variables do not 
meet proportional hazard assumptions because 
the significance value of all variables was less 
than the α value of 0.05. 
Based on the analysis, the variables related 
to the survival of Type II Diabetes Mellitus 
patients are the interaction of gender variables 
with age variables (p<0.05; HR = 0.841; CI 
95% 0.711-0.993), variable interaction of 
blood glucose levels during with variable age 
(p <0.05; HR = 1,061; CI 95% 1,028-1,096), 
variable interaction of blood glucose levels 
when with concomitant disease variables (p 
<0.05; HR 1,221; CI 95% 1,036-1,438), and 
variable interaction of blood glucose levels 
with variable treatment profiles (p <0.05; HR 
= 0.824; CI 95% 0.747-0.909).  
 
DISCUSSION 
The Kaplan-Meier survival curve analysis 
aims to find out an overview of the 
characteristics of survival time. In addition, the 
Kaplan Meier curve is also used to assess 
proportional hazard assumptions.   To see the 
difference in survival curve can be made 
statistically testing by using the Log Rank test. 
Log-Rank test is intended to determine the 
difference in survival curve between groups of 
factors that affect the survival of patients with 
type II diabetes mellitus. In addition to using 
the Kaplan Meier curve, to see the difference in 
survival curve can be done statistically testing 
by using the Log Rank test.  Test value of 2.010 
with a degree of freedom of 1 and p-value of 
Log Rank test result of 0.156. The results of this 
test will be compared to the α value of 5%. The 
p-value value is greater than the α hence the 
decision to accept H0, which means there is no 
difference in the survival curve based on 
gender. 
Figure 1a shows the curve position of type 
II diabetes mellitus patients who were female 
and male close to each other in the    0th to 3rd    
year.  In year 4, the curve position of the patient 
with the male gender is below the curve of the 
female patient.  This revealed  that  in the    0th 
to  3rd  year, both  women  and  men have a 
relatively  similar level of  survival  probability,   
while in the 4th  year, the probability of survival 
of male  patients is lower   than that of  female 
patients,   so  descriptively  there was  a  
difference  in the survival  curve of type  II  
diabetes  mellitus  patients based on  the  
gender suffered   
Kaplan Meier's curve in Figure 1 shows the 
curve position of patients diagnosed with type II   
diabetes mellitus at the age of ≥45 years is 
below the curve of patients who are recorded as 
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diagnosed with type II diabetes mellitus aged 
<45 years. The <45 years old patient curve also 
showed a reasonably slow decline until the 10th 
year was still above 0.8. These results state that 
the probability of survival of patients diagnosed 
at the age of <45 years is higher than patients 
diagnosed with type II diabetes mellitus at the 
age of ≥45 years. The Log Rank test analysis 
obtained a result of 2,899 with a degree of 
freedom of 1 and a p-value of 0.089. This result 
is then compared to α by 5%, then obtained a 
p-value more significant than α. Hence, the 
decision to accept H0 means there is no 
difference in the survival curve of type II 
diabetes mellitus patients based on the initial 
age of diagnosis. 
Figure 1c, the curve of a multi-diagnosed 
patient is at the very bottom compared to the 
curve of the patient diagnosed with other 
complications. This indicates that patients with 
multiplication have a lower probability of 
survival than other complications. Statistically, 
the Log Rank test obtained 36,627 with a degree 
of freedom of 7 and a p-value of 0.000. This 
value is compared to the α value of 5%. The 
results showed that the value of p-value is less 
than α, hence the decision to reject H0, which 
means there is a difference in the survival curve 
of type II diabetes mellitus patients based on 
complications suffered. 
Figure 1d shows the curve position of type II 
diabetes mellitus patients with comorbidity 
below the curve of type II diabetes mellitus 
patients without comorbidity. It appears that the 
survival curve of patients without comorbidity 
is above 0.8. In contrast, the survival curve of 
patients with comorbidity continues to decrease 
below the line of 0.8. This result shows that the 
probability of survival of type II diabetes 
mellitus patients without comorbidity is better 
compared to patients with type II diabetes 
mellitus with comorbidity. However, based on 
statistics,  the Log Rank test results from 3,444, 
a degree of freedom of 1, and a value p-value is 
0.064. Thus, the value of p-value is greater than 
the value of α 5%, which states that there is no 
difference in the curve of type II diabetes 
mellitus patients based on comorbidity. 
Based on Figure 1e, type II diabetes 
mellitus  II patients with insulin therapy are 
well below the curve of type II diabetes 
mellitus patients with oral antidiabetics. It is 
also below the curve  type II diabetes mellitus 
patients who receive insulin-oral antidiabetic 
combination therapy. This indicates that the 
survival of patients with insulin therapy is 
lower than patients with oral antidiabetics or 
insulin-oral antidiabetics combination. The 
curve of patients receiving oral antidiabetic 
therapy dropped quite slowly until the 10th 
year was still above the 0.8 line. This means 
the probability of survival of type II diabetes 
mellitus patients receiving oral antidiabetic 
therapy is high. Statistical analysis using Log 
Rank shows a test result of 117.655 with a 
degree of freedom of 2 and a value p-value of 
0.001. This value is then compared to the α 
value of 0.05%. The results showed a value of 
p-value more minor than the value of α, so the 
decision to reject H0 means there is a difference 
in the survival curve of type II diabetes mellitus 
patients based on treatment profile. 
In Figure 1f, the curve position of type II 
diabetes mellitus patients who have normal 
blood glucose levels is below the curve of type 
II diabetes mellitus patients who have 
moderate and high blood glucose levels. These 
results show that the survival of type II 
diabetes mellitus patients who have average 
blood glucose tends to below. In statistical 
analysis, Log Rank test results were obtained at 
7,793 with a degree of freedom of 2 and a p-
value value of 0.020. This value is then 
compared with an α value of 5%, where the p-
value is less than α. Hence, the decision to reject 
H0 means there is a difference in the survival 
curve of type II diabetes mellitus patients based 
on current blood glucose levels. 
The table shows that every year of age 
increases in type II diabetes mellitus patients, 
both male and female, the probability of death 
increases by 0.841 times. Meanwhile, every 
one year of diabetes mellitus type II patients 
followed by consistently high blood glucose 
levels, the probability of death increased by 
1,401 times. Sanusi et al., in their research, 
stated that the younger the patient's age, the 
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longer his life-assurance time will be. Patients 
under 45 had a 0.015 times lower risk of failure 
than patients over 45.20 Shaik et al. state that if 
the age of diabetic patients increases, then the 
risk of death also increases simultaneously.21 
Based on blood glucose levels, patients with 
high blood glucose levels had a 1,128 times 
greater risk of failure than patients with 
low/normal blood glucose levels. Dewi et al. 
also stated that patients with type II diabetes 
mellitus with high and low blood glucose 
levels have a 1,587 times faster risk than 
patients with regular/stable blood glucose 
levels. In addition, female type II diabetes 
mellitus patients had a 1,557-fold risk of 
failure than male type II diabetes mellitus 
patients.22 The amount of comparison between 
the composition of estradiol will make the 
estrogen receptor gene (ER), and estradiol 
receptor in women activated. It causes the 
metabolic process to work, and both genes will 
coordinate insulin sensitivity and increased 
glucose uptake in the blood. In line with the 
increasing age of humans, the hormone 
estrogen will decrease, causing insulin 
sensitivity, and blood glucose uptake will 
drop.23 
Patients with complications and received a 
treatment profile of insulin combination 
therapy + oral antidiabetics, the probability of 
experiencing the event of death 1,061 times. 
The hazard ratio for the interaction of blood 
glucose levels during and treatment profile was 
0.824. This result means patients with current 
blood glucose levels and receiving insulin-oral 
antidiabetic combination therapy have a 0.824 
chance of dying compared to patients with 
regular/moderate blood glucose levels and 
receiving oral/insulin antidiabetic therapy. In 
addition, the patient's death probability with 
high blood glucose levels and comorbidity 
increased by 1,221 times compared to patients 
with normal blood glucose levels and without 
comorbidity. Dewi et al. stated that patients 
with type II diabetes mellitus without the 
concomitant disease had a 0.640 times lower 
risk of failure than type II diabetes mellitus 
patients with the concomitant disease.22 
Another study conducted by Putri stated the 
chances of diabetes mellitus patients who did 
not have another diagnosis 3.60 times 
compared to diabetes mellitus patients who 
had a diagnosis of lain.24 
According to research, 84.1% of type II 
diabetes mellitus patients with complications 
have a poor quality of life. The longer a patient 
has diabetes, the greater the risk of developing 
complications.25 In contrast, Derebew stated 
that patients who received only oral 
antidiabetic therapy and received oral 
antidiabetic therapy combined with insulin had 
a longer recovery time than patients who 
received only insulin therapy.26 Combination 
therapy with multitarget more provides the 
benefits of treatment achieved aggressively. 
According to the Directorate General of 
Pharmaceutical and Medical Devices, the 
combination of insulin-oral antidiabetic and 
the combination between oral antidiabetic is 
used to obtain controlled blood glucose effects 
at all times and minimize side effects as well 
as reduce the risk of acute complications and 
inhibit the progression of microangiopathy and 
macroangiopathy.27 
Hazard H(t) function shows that patients 
with type II diabetes mellitus in the 0th to 10th 
year have increased, meaning that the risk of 
patients experiencing failure (death) is higher 
(Table 4). S(t) from year 0 to year 10 decreased 
in survival function, which means the patient's 
probability of survival is lower. This is not 
following Putri's research, which states that the 
longer the patient suffers from diabetes 
mellitus, the higher the patient's survival 
ability to diabetes mellitus.24 The greater the t 
value, the smaller the S(t) value, while the 
cumulative hazard indicates that the greater the 
t time, the greater the H(t) value will tend to be 
the more significant. This means that the 
patient's probability of surviving until t time 
will be more negligible (close to zero), and the 
risk of dying will be greater.28 
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Table 4.  Survival Table of Type II Diabetes Mellitus Patients at PKU Muhammadiyah Gamping 





0 0,017 0,973 
1 0,027 0,959 
2 0,035 0,947 
3 0,045 0,933 
4 0,063 0,908 
5 0,071 0,896 
6 0,082 0,880 
7 0,109 0,844 
8 0,130 0,817 
9 0,148 0,795 
10 0,165 0,775 




Factors that affect the survival of patients 
with type II diabetes mellitus are gender, age, 
diagnosis of complications, comorbidity, 
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